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ARTICLE
The Tec kinase ITK is essential for ILC2 survival
and epithelial integrity in the intestine
Hyoung-Soo Cho 1, Andrea Reboldi1, Jason A. Hall2 & Leslie J. Berg 1
Innate lymphoid cells (ILC) are lymphocytes that lack an antigen-speciﬁc receptor and are
preferentially localized in non-lymphoid tissues, such as mucosal barriers. In these locations
ILC respond to tissue perturbations by producing factors that promote tissue repair and
improve barrier integrity. We show that mice lacking the Tec kinase ITK have impaired
intestinal tissue integrity, and a reduced ability to restore homeostasis after tissue damage.
This defect is associated with a substantial loss of Type 2 ILC (ILC2) in the intestinal lamina
propria. Adoptive transfer of bone marrow ILC2 precursors conﬁrms a cell-intrinsic role for
ITK. Intestinal ILC2 numbers in Itk-/- mice are restored by the administration of IL-2 com-
plexes, also leading to improved intestinal tissue damage repair. Reduced Bcl-2 expression in
intestinal Itk-/- ILC2 is also restored to WT levels after IL-2 complex treatment, indicating a
tissue-speciﬁc role for ITK in ILC2 survival in the intestine.
https://doi.org/10.1038/s41467-019-08699-9 OPEN
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Innate lymphoid cells are one of a subset of lymphocytes thatlack an antigen-speciﬁc receptor; yet, they produce effectormolecules shared with CD4+ T cells1–4. Whereas adaptive
lymphocytes are abundant in lymphoid tissues, ILC are pre-
ferentially localized in non-lymphoid tissues, most notably at
mucosal barriers5. Their positioning at mucosal surfaces confers a
strategic advantage to ILC, allowing them to respond promptly to
bacterial or viral infections6–9. ILC are thought to be important in
regulating mucosal barriers by triggering epithelial cell growth or
modulating tissue integrity and homeostasis5,10. ILC subsets can
be categorized into cytotoxic ILC and non-cytotoxic helper-like
ILC. Each helper-like ILC subset expresses a key transcription
factor that regulates a distinct cytokine proﬁle corresponding to
their adaptive CD4+ T cell counterparts: T-bet for ILC1, GATA-3
for ILC2, and RORγt for ILC31,2,4.
ILC2 were ﬁrst identiﬁed in mesenteric lymphoid clusters and
were later shown to be scattered in the lung and intestinal lamina
propria (LP)11–13. ILC2 express a set of surface markers (e.g.,
CD90, CD127, CD25, IL-25R, and IL-33R) along with the sig-
nature transcription factor, GATA-31,3,14. ILC2 are known to be
activated by alarmins, such as IL-25, IL-33, and thymic stromal
lymphopoietin (TSLP)11–13,15,16. Upon stimulation by these
cytokines, ILC2 produce IL-5, IL-9, IL-13, and amphiregulin
(Areg), which are important effector molecules in responses to
helminths in the intestine and promote repair of tissue damage
caused by virus infections in the lung6,17,18. In addition, IL-2
regulates ILC2 production of IL-5 and IL-9, and IL-2/anti-IL-2
complexes (IL-2c) are known to induce in vivo proliferation of
ILC219,20.
ILC emerge from their lymphoid progenitors in the fetal liver
and adult bone marrow (BM) and disseminate to various tis-
sues21,22. ILC precursors express integrin α4β7, the receptor for
mucosal vascular addressin cell adhesion molecule 1 (MAdCAM-
1), an integrin ligand expressed by gut-associated endothelial
cells23. Additionally, ILC precursors express CCR9, a key homing
molecule that guides cells to intestinal tissues. Previous studies
showed that retinoic acid (RA) upregulates the expression of
integrin α4β7 and CCR9 in ILC1 and ILC3 for gut-homing24.
However, BM ILC2 precursors (ILC2P) are programmed to
express these gut-homing receptors, which promote direct gut-
homing of ILC2P in an RA-independent manner24. In addition to
gut-homing, ILC2 dissemination also requires efﬁcient egress of
ILC2P from the BM, a process regulated by IL-3325. Thus, ILC2
trafﬁcking to peripheral sites is a cooperative process combining
successful egress with proper tissue homing.
Despite a lack of antigen-speciﬁc receptors, ILC express a series
of T-cell receptor (TCR) components, such as LAT, LCK, ICOS,
and the Tec family kinase ITK22,23,26–28. Transcriptome analysis
revealed that ILC have more similarities with T cells than with
other adaptive lymphocytes29, but the function of TCR compo-
nents in ILC has not been characterized. Interestingly, Shih et al.
recently reported that ITK and IRF4, a TCR downstream tran-
scription factor, were found among the most highly upregulated
genes in ILC230. Consistently, RNA-Seq data from the Immu-
nological Genome Consortium (www.immgen.org) shows that Itk
expression is highly elevated in intestinal ILC2 compared with
other ILC subsets in that tissue; in addition, a recent study reports
that ILC2 isolated from a variety of tissue sites all express sub-
stantial amounts of Itk mRNA31. Interestingly, ITK is also known
to be important for CD4+ T-cell migration to the intestine32.
However, the role of ITK in type 2 innate lymphoid cells has not
previously been assessed.
Here, we examine the function of ITK in ILC2 in the intestine.
We show that Itk-−/−mice display a tissue-speciﬁc loss of ILC2 in
the intestine but not other sites. While Itk−/− mice have neither
deﬁciency of BM ILC2P nor of gut-homing receptor expression
on ILC2, adoptively transferred Itk−/− ILC2 could not be
recovered in the intestine of Rag1−/−Il2rg-−/− hosts, indicating a
cell-intrinsic defect in Itk−/− ILC2. Intestinal tissue damage fol-
lowing DSS treatment is more severe in Itk−/− mice; however,
injection of IL-2c into Itk−/− mice restores intestinal ILC2
numbers and improves the response of Itk−/− mice to DSS.
Overall, our data indicate that ITK is essential for ILC2 tissue
homeostasis in the intestine and for intestinal barrier integrity.
Results
ITK deﬁciency leads to a steady-state defect in gut ILC2. Gene
expression data indicate that Itk is highly expressed in intestinal
ILC2, at levels comparable with those seen in T cells; furthermore,
high expression of Itk was not shared with gut ILC1 or ILC3
(www.immgen.org). To determine whether ITK might function in
ILC2, we isolated lymphocytes from small and large intestinal LP
of WT and Itk−/− mice and analyzed ILC2 populations. In both
small and large intestine, ILC2 frequency in Itk−/− mice was
signiﬁcantly reduced compared with WT (3–6-fold; Fig. 1a, b),
and the numbers of ILC2 in both intestinal tissues were 6–7-fold
lower in Itk−/− mice relative to controls (Fig. 1c). Ex vivo sti-
mulation of LP lymphocytes also demonstrated that ITK-deﬁcient
ILC2 were impaired in cytokine production (Fig. 1d, e). ILC2
deﬁcit was restricted to the intestinal tissues, as BM, lung, and
mesenteric lymph nodes (mLN) of Itk−/− mice showed no
reduction in ILC2 proportions compared with controls (Fig. 1f,
g). Furthermore, assessment of steady-state intestinal ILC1, ILC2,
and ILC3 examined together using the gating strategy outlined in
Supplementary Fig. 1A indicated that intestinal ILC2 were the
only subset profoundly affected ITK deﬁciency (Fig. 1h and
Supplementary Fig. 1B). These data demonstrate that the absence
of ITK speciﬁcally affects the ILC2 in the gut, but not other ILC
populations, or ILC2 in other tissue sites.
Impaired gut ILC2 expansion in virus-infected Itk−/− mice.
Pulmonary viral infections have been shown to induce substantial
increases in lung ILC2 numbers7,33,34. To assess the responses of
Itk−/− ILC2 to virus, we infected WT and Itk−/− mice with
mouse gammaherpesvirus-68 (MHV68) by the intranasal route
(103 PFU). As previously described for respiratory syncytial virus
(RSV) or inﬂuenza A virus (IAV) infection, intranasal MHV68
infection induced a twofold increase in lung ILC2 at D7, with a
further increase at D14 compared with uninfected controls
(Supplementary Fig. 2A-B vs. Fig. 1f, g). This response was not
altered in the absence of ITK. We then challenged WT and Itk−/−
mice with MHV68 via intraperitoneal inoculation (106 PFU), as
MHV68 has been shown to replicate in the gastrointestinal (GI)
epithelium35,36. As shown, ILC2 in the siLP and cLP of WT mice
showed a twofold increase at D7 compared with uninfected
controls; steady-state proportions of intestinal ILC2 were restored
in WT mice by D14 (Supplementary Fig. 2C, D vs. Fig. 1a, b). In
contrast, intestinal ILC2 in Itk−/− mice remained at low levels
after infection, at both D7 and D14 (Supplementary Fig. 2C-D).
We also examined other ILC subsets in the intestine after
MHV68 by IP inoculation. Although there were modest decreases
in ILC3 and ILC1 in cLP of Itk−/− mice at D14 compared with
WT, no signiﬁcant differences were consistently observed in
intestinal ILC3 or ILC1 in MHV68-infected WT versus Itk−/−
mice at both timepoints, as was seen for intestinal ILC2
(Supplementary Fig. 3). To determine whether gut ILC2 were
required for effective viral control in the intestine, we challenged
Roraﬂ/ﬂ x Il7ra-Cre (Roraﬂ/ﬂ) mice or littermate controls (Rora+/+
and Rora+/ﬂ) with IP MHV68 infection, as Roraﬂ/ﬂ mice are
known to lack ILC2 in all tissues16. Despite this ILC2 deﬁciency,
Roraﬂ/ﬂ mice had similar MHV68 viral genome copy numbers in
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both the spleen and small/large intestine at D14 compared with
controls (Supplementary Fig. 4). Collectively, these data indicate
that Itk−/− mice have an intestinal ILC2 deﬁcit that cannot be
overcome by a lytic viral insult to the GI epithelium.
BM Itk-/- ILC2P have normal gut-homing receptor expression.
Our examination of ILC2 in the BM showed a modest increase in
the proportions of these cells in Itk−/− mice compared with WT
(Fig. 1f). To assess whether ITK might function in ILC2 devel-
opment, we performed additional characterization of BM ILC2
precursors. After depleting lineage-positive cells, we compared
the frequencies and numbers of ILC2 precursors in naïve WT and
Itk−/− mice. Similar to our ﬁndings shown above in the absence
of lineage depletion (Fig. 1f), lineage-depleted population analy-
ses revealed modest increases in the frequency and cellularity of
Itk−/− BM ILC2P compared with WT (Fig. 2a, b). However, the
magnitude of these changes was far smaller than the reduction in
ILC2 numbers seen in the intestinal tissue of Itk−/− mice
(Fig. 1a–c).
Compared with other ILC subsets, ILC2 precursors in the BM
have been shown to express gut-homing receptors, CCR9 and
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Fig. 1 Itk−/− mice have a gut-speciﬁc reduction in ILC2. a–c The proportions of ILC2 (GATA-3+ CD127+) in the lamina propria of the small (siLP) or large
intestine (cLP) from naïve WT and Itk−/−mice are shown after gating on lineage-negative cells (CD3ε− CD19− TCRβ− TCRγδ− CD11b− CD11c−). a Graphs
show compilations of intestinal ILC2 proportions (b) and numbers (c) in the siLP and cLP. d, e IL-5 and IL-13 production from siLP and cLP ILC2 (lineage-
negative CD90.2+Sca-1+) from naïve WT and Itk−/− mice. f, g ILC2 proportions from the bone marrow (BM), lung, and mesenteric lymph nodes (mLN) of
naïve WT and Itk−/− mice (f) along with compilations of data (g). h The proportions of various ILC subsets in the siLP and cLP were analyzed. Intestinal
ILC2 and ILC3 frequencies were enumerated from the gating shown in Supplementary Fig. 1 A. Data are the compilation of 2–3 independent experiments
using WT (n= 4–6) and Itk−/− mice (n= 4–6). Statistical signiﬁcance was analyzed using Student’s t tests (n.s., not signiﬁcant; *p < 0.05; **p < 0.01;
***p < 0.001). Source data are provided as a Source Data ﬁle
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integrin α4β7, and to trafﬁc efﬁciently to the intestine without
requiring priming in secondary lymphoid organs8,24,26. There-
fore, we examined gut-homing receptor expression on BM ILC2P
from WT and Itk−/− mice. As shown, we did not observe any
signiﬁcant differences in the expression of CCR9 and integrin
α4β7 between Itk−/− ILC2P and WT ILC2P (Fig. 2c, d). We also
examined ILC2-associated cytokine receptors, IL-25R, IL-33R,
and CD25 (Fig. 2e, f), and surface markers, CD90, Sca-1, and
KLRG-1 (Fig. 2g, h). While we found modest reductions of IL-
33R and CD25 expression on Itk−/− ILC2P compared with
controls, the magnitude of these changes was small. Taken
together, these data overall do not reveal major differences
between WT and Itk−/− ILC2P in the BM. Furthermore, the data
indicate that the ITK deﬁciency is not likely to affect the gut-
homing potential of ILC2 generated in the BM, at least not due to
altered expression of gut-homing receptors.
ITK is dispensable for gut-homing receptors on gut ILC2. To
investigate further a potential role for ITK in gut-homing
receptor expression on ILC2, we assessed CCR9 and integrin
α4β7 levels on ILC2 in the small and large intestinal LP from
naïve WT and Itk−/− mice. In spite of being present at reduced
cellularity, the expression levels of homing receptors on Itk−/−
ILC2 from the small intestinal LP were similar to those on WT
ILC2 from this site (Fig. 3a, b, left panel). In the colonic LP, CCR9
expression on Itk−/− ILC2 shown was modestly reduced com-
pared with that on WT cLP ILC2, whereas integrin α4β7
expression levels were similar (Fig. 3a, b, right panel).
As previously reported, retinoic acid (RA) is neither required
for the expression of gut-homing receptors nor for the tissue
homing ability of ILC2 to the intestine24. Nonetheless, we
investigated the effects of TGF-β and/or RA on ILC2 gut-homing
receptor expression in the absence of ITK. For this analysis, we
isolated lineage-depleted WT and Itk−/− BM cells and cultured
them in vitro with IL-2, IL-7, and IL-33 in presence of RA and/or
TGF-β for 5 days. As shown, and consistent with previously
reported data24, we neither observed any detectable differences in
integrin α4, integrin β7, or CCR9 expression on cultured BM
ILC2P in response to RA alone, nor did we observe differences
between WT and Itk−/− ILC2P (Supplementary Fig. 5A and
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Fig. 2 BM Itk−/− ILC2P exhibit normal gut-homing receptor expression. a, b The proportions and numbers of WT and Itk−/− ILC2 precursors were
analyzed from lineage-depleted BM cells. c–h The expression of gut-homing receptors, CCR9 and integrin α4β7 (c, d, top panel), cytokine receptors, IL-
25R, IL-33R, and CD25 (e, f, middle panel), and ILC2 markers, CD90, Sca-1, and KLRG-1 (g, h, bottom panel), on WT and Itk−/− BM ILC2P were analyzed.
Data are the compilation of 2–3 independent experiments using WT (n= 4–7) and Itk−/− mice (n= 4–7). Bar graphs with error bars show the averages
and the SEMs. Statistical signiﬁcance was analyzed using Student’s t tests (n.s., not signiﬁcant; *p < 0.05; **p < 0.01; ***p < 0.001). Source data are
provided as a Source Data ﬁle
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5D–F). TGF-β alone had divergent effects on integrin α4 and
integrin β7 in both WT and Itk−/− ILC2P (Supplementary
Fig. 5B, D and E). In combination, RA plus TGF-β induced both
CCR9 and integrin α4β7 on BM ILC2P, with only modest
differences seen by ILC2P from WT versus Itk−/− mice
(Supplementary Fig. 5C and 5D–F). Taken together, these data
indicate that ITK is not strongly regulating the expression levels
of gut-homing receptors on ILC2 in response to RA and TGF-β
stimulation.
Itk−/− ILC2 show a modest defect in response to IL-33. Based
on our ﬁndings that Itk−/− ILC2 showed modest reductions in
IL-33R expression, we considered whether these cells might have
impaired responses to IL-33. To determine this, we cultured
lineage-depleted BM cells with IL-2 plus increasing doses of IL-33
(5.0–50 ng/mL) for 2 days and compared the expansion of ILC2
in the populations of WT and Itk−/− BM cells. In the presence of
IL-2 plus IL-33, both WT and Itk−/− BM cells showed a com-
parable ILC2 induction in response to comparatively low IL-33
concentrations (5.0–25 ng/mL); however, at the highest dose of
IL-33 (50 ng/mL), we observed a modest reduction in the pro-
portions of ILC2 in Itk−/− BM versus control BM cultures
(Fig. 4a, b). Next, we assessed the proliferation of BM-derived
ILC2P in response to IL-33. We labeled lineage-depleted BM cells
with CellTrace Violet and compared proliferation in response to
IL-33 after 2 days in the presence of IL-2 ± IL-33. IL-33 induced
substantial cell proliferation of WT BM cells. In contrast, ITK-
deﬁcient BM cells underwent signiﬁcantly less proliferation
(Fig. 4c). Analyses of the percentages of cells in each division peak
conﬁrmed that Itk−/− BM cultures had increased proportions of
undivided cells and had reduced percentages of cells in peaks
representing 2–4 cell divisions compared with controls (Fig. 4d).
As we observed modest increases in the numbers of Itk−/−
ILC2P in the BM compared with controls (Fig. 2b) and reduced
expression of IL-33R on these cells (Fig. 2e and f), we considered
whether ITK might regulate BM egress of ILC2P via expression of
CXCR4. CXCR4 has been found to promote tissue retention of
lymphocytes in the BM37. Therefore, we compared CXCR4
expression of untreated BM ILC2P directly ex vivo from naïve
WT and Itk−/− mice and also examined CXCR4 expression after
culture of lineage-depleted BM cells with IL-2 for 48 h. We found
no differences in CXCR4 expression on Itk−/− versus WT BM
ILC2P directly ex vivo, and a slight reduction on Itk−/− BM
ILC2P after culture in IL-2 (Fig. 4e, f). We then assessed whether
Itk−/− ILC2P showed impaired CXCR4 downregulation after
culture in IL-33, as this response was reported as a mechanism
controlling ILC2P egress from the BM25. To test this hypothesis,
we cultured lineage-depleted WT BM cells with IL-2 plus varying
doses of IL-33 (1.0–10 ng/mL) in the presence or absence of
PRN694 (25 or 50 nM), an ITK small molecule inhibitor. After
2 days, cells were examined for CXCR4 expression. In our hands,
IL-33 did not promote CXCR4 downregulation on ILC2P in
cultured lineage-depleted BM cells; however, ITK inhibition did
promote a modest upregulation of CXCR4 in the presence of a
high dose of IL-33 (10 ng/mL) (Fig. 4g, h). Taken together, these
data indicate that the absence or inhibition of ITK had a modest
effect on IL-33-induced ILC2 proliferation and only very subtle
effects on CXCR4 expression.
Last, we tested the efﬁcacy of IL-33-driven ILC2 induction
in vivo by injecting IL-33 into WT and Itk−/− mice, and then
assessing the frequencies of ILC2 in various organs. As expected,
IL-33 injection increased the ILC2 frequencies in mLN and
peritoneal cavities of WT mice, with a similar magnitude of
change seen in Itk−/− mice (Fig. 4i). These results indicated that
Itk−/− ILC2 had no intrinsic defect in responding to IL-33
in vivo. Interestingly, however, IL-33 injection failed to induce
intestinal ILC2 increases in siLP and cLP of Itk−/− mice, whereas
WT mice showed clear increases in ILC2 in these tissues (Fig. 4i).
These data indicate IL-33 injection in vivo is not sufﬁcient to
induce an effective ILC2 population increase in the intestines of
Itk−/− mice.
ITK has a cell-intrinsic function in gut ILC2 homeostasis. Our
overall ﬁndings with BM ILC2 precursors indicated that the
absence of ITK was not profoundly affecting ILC2 maturation.
Nonetheless, Itk−/− mice consistently exhibited a defect in
intestinal ILC2 that could not be restored by in vivo adminis-
tration of IL-33. We considered whether this gut-speciﬁc defect in
ILC2 might result from an altered environment in the intestines
of Itk−/− mice caused by dysregulation of Itk−/− T cells, a pos-
sibility raised by previous studies indicating cross-talk between
T cells and ILC in the intestine16,17. First, we generated mixed
WT:Itk−/− BM chimeras in lethally irradiated hosts. The goal of
this experiment was to provide a WT environment, including the
presence of WT intestinal T cells, in which to assess the devel-
opment and homeostasis of ILC2 arising from Itk−/− BM pre-
cursors. However, as shown in Supplementary Fig. 6, we failed to
recover adequate numbers of cells from the recipients due to
lethality after BM transplantation. As an alternative, we crossed
Itk−/− mice to Rag2−/− mice, and assessed ILC2 frequencies in
the intestine in the absence of T cells. As shown in Fig. 5a and b,
ILC2 frequencies in the cLP of Rag2−/− Itk+/− or Rag2−/− Itk−/−
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littermates were reduced compared with those seen in cLP of
Rag2−/− Itk+/+ littermates. These results support an ILC2-
intrinsic role for ITK in ILC2 homeostasis in the intestine that is
independent of the presence of T cells. In a second experiment,
we addressed whether the absence of ITK altered the migration
and/or survival of ILC2 in the intestine after adoptive transfer. To
examine this, we cultured lineage-depleted WT and Itk−/− BM
cells with IL-2, IL-7, and IL-33 in the presence of RA plus TGF-β,
to fully induce gut-homing receptors in vitro. After culture for
3 days, we enriched cultured cells with CD25 MicroBeads to
further isolate ILC2, and then adoptively transferred these cells
into Rag1−/− Il2rg−/− hosts, which have neither adaptive
immune cells nor innate lymphocytes. At day 3 post transfer, we
isolated lymphocytes from mLN, siLP, and cLP to examine the
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frequencies of transferred ILC2. We observed that WT ILC2
could be efﬁciently recovered from the gut-draining LN and LP of
both the small and large intestine, and were abundantly repre-
sented in cLP tissue (Fig. 5c, d). In contrast, Itk−/− ILC2 numbers
were greatly reduced in all intestinal tissues compared with WT
ILC2 (Fig. 5c, d). We also analyzed the expression levels of CCR9
and integrin α4β7 on transferred WT and Itk−/− ILC2 in siLP
and cLP. Although CCR9 expression was reduced on siLP of Itk
−/− ILC2, no other differences between WT and Itk−/− trans-
ferred ILC2 were observed (Fig. 5e, f). ILC2 isolated from the
spleen and mLN of recipients also failed to reveal prominent
differences in gut-homing receptor expression between trans-
ferred WT and ITK-deﬁcient cells (Supplementary Fig. 7). Taken
together, these data show that a deﬁciency in ITK leads to a cell-
intrinsic defect in ILC2 recovery from the gut tissue, but suggest
that the underlying cause of this defect is unlikely to be due to
impaired gut-homing receptor expression.
ITK deﬁciency affects intestinal tissue integrity. Our results
thus far indicated that the absence of ITK caused an intestinal
ILC2 defect. Given the reparative function of intestinal ILC2 in
helminthic infection or autoimmune disease conditions11–13,38,
we considered whether the intestinal ILC2 defect in Itk−/− mice
affected GI tissue integrity and repair from intestinal damage. To
test this, we challenged WT and Itk−/− mice with 3.0% DSS-
dissolved water for 5 days to induce intestinal damage, and then
restored normal drinking water for an additional 10 days to
monitor intestinal tissue repair (Fig. 6a). As shown in Fig. 7b,
DSS-treated WT mice exhibited weight loss beginning at day 5
post treatment and then recovered and gradually regained lost
weight starting at day 9 (Fig. 6b). In contrast, Itk−/− mice dis-
played an immediate weight loss beginning on day 1, and showed
a continuous weight loss during the recovery period (D6-D15)
(Fig. 6b), consistent with impaired amphiregulin production
by Itk−/− intestinal ILC2 under steady-state conditions (Fig. 6c,
d). Failure to recover from the DSS-induced damage was
ultimately fatal in Itk−/− mice (n= 7, mean survival= 11.0 days),
while DSS-treated WT mice showed no lethality (n= 6) (Fig. 6e).
Consistent with these data, histological analysis of DSS-treated
Itk−/− colons at D7 post treatment revealed more cellular inﬁl-
trates than seen in WT colon histology at D7 (Fig. 6f), and the
length of Itk−/− colons (n= 5) was shorter compared with WT
colons (n= 5), indicating more severe inﬂammation in the colons
of Itk−/− mice (Fig. 6g). As expected, the frequencies of ILC2 in
Itk−/− colonic LP were greatly reduced in DSS-treated Itk−/−
mice compared with controls, as we observed under steady-state
conditions (Fig. 6h). The role of ILC2 in the maintenance of
tissue integrity is mediated by effector cytokines produced by
these cells, such as IL-5 and IL-13, which induce tissue repair,
mucus production, and goblet cell hyperplasia39. Therefore, we
performed intracellular cytokine staining for IL-5 and IL-13
with isolated colonic LP lymphocytes from DSS-treated WT and
Itk−/− mice at D7 post treatment. As shown in Fig. 6i and j, IL-5
and IL-13 production from cLP ILC2 in Itk−/− mice was sig-
niﬁcantly reduced in comparison with the production from WT
cLP ILC2.
To independently test whether Itk−/− mice had impaired
intestinal tissue integrity, we administered FITC-dextran to
untreated WT and Itk−/− mice via oral gavage, and compared
the levels of serum FITC-dextran after 4 h as an indicator of
intestinal permeability. Consistent with our ﬁndings in the DSS-
induced colitis model, we observed a higher level of FITC-dextran
in the serum collected from Itk−/− mice than WT mice (Fig. 6k).
These data strongly suggest that ITK deﬁciency, associated with the
ILC2 defect in the colon, leads to impaired intestinal integrity under
steady-state conditions, as well as in response to intestinal damage.
IL-2 complex injection restores gut ILC2 in Itk−/− mice. Our
results outlined above indicated a defect in gut-homing migration
of ILC2 in Itk−/− mice. We considered whether this defect might
be due to impaired ILC2 homeostasis in the gut, as a component
of the failure to observe high numbers of Itk−/− ILC2 in the
intestinal tissues of Rag−/−Il2rg−/− mice after adoptive transfer.
Speciﬁcally, we considered whether the ITK deﬁciency might
contribute to a defect in ILC2 cell survival in the gut as a result of
a reduced IL-2 production by Itk−/− T cells19,40. To test this
hypothesis, we mixed IL-2 and anti-IL-2 mAb (JES6-1) to make
IL-2 complexes (IL-2c), and injected these complexes daily into
WT and Itk−/− mice. After 4 days, we analyzed ILC2 in the
intestines. As reported previously19,20,40, IL-2c injection into WT
mice increased the frequencies of ILC2 (CD90+ Sca-1+) in siLP
and cLP compared with PBS-injected control mice (Fig. 7a, b).
Surprisingly, IL-2c injection into Itk−/− mice showed a profound
effect on ILC2, leading to complete restoration of ILC2 propor-
tions and numbers in the siLP and cLP, to a level similar to that
seen in IL-2c-treated WT mice (Fig. 7a, c). In contrast, injection
of these IL-2c had only modest effects on the numbers of FoxP3+
CD4+ T cells (Treg), and no effect on the numbers of conven-
tional (FoxP3−) CD4+ T cells in the intestinal tissue of either WT
or Itk−/− mice (Supplementary Fig. 8A–D).
To determine whether restoration of ILC2 in the intestine of
Itk−/− mice by IL-2c improved the responses of these mice to
intestinal tissue damage, we treated mice with DSS (Fig. 7d).
Although IL-2c treatment provided a marginal improvement in
weight loss after DSS-induced damage in WT mice, IL-2c-treated
Itk−/− mice were markedly improved compared with controls
(DSS but no IL-2c; Fig. 7d). In fact, IL-2c treatment of Itk−/−
mice restored their ability to respond to intestinal tissue damage
to that of control-treated WT mice.
These ﬁndings suggested that Itk−/− intestinal ILC2 might
have impaired survival potential, leading to their reduced
numbers and inability to expand in numbers following virus-
induced or chemical-induced intestinal tissue damage. To assess
this, we ﬁrst examined Annexin V staining on siLP and cLP
Fig. 4 Itk−/− ILC2 responses to IL-33 are modestly impaired. a, b Lineage-depleted WT and Itk−/− BM cells were cultured with IL-2 plus IL-33 (5.0 to 50
ng/mL) for 2 days and analyzed for ILC2 precursors (a). Compiled data from two independent experiments are shown (b). c, d Lineage-depleted WT and
Itk−/− BM cells were labeled with CellTrace Violet and assessed for IL-33-induced proliferation after 2 days culture (c). Compiled percentage of cells in
each cell division peak from two individual experiments is shown (d). e–h CXCR4 expression on lineage-depleted BM WT and Itk-−/− ILC2 precursors was
analyzed in the presence or absence of IL-2 after 2 days culture (e). Compiled MFIs from three independent experiments are shown (f). CXCR4 expression
on cultured BM WT ILC2P was analyzed in the presence or absence of PRN694 after culture with IL-2 and IL-33 for 2 days (g). Calculated MFIs from the
compilation of two experiments are shown (h). iMice were injected daily with IL-33 for 7 days, and the percentages of ILC2 from mesenteric lymph nodes,
peritoneal cavity exudates, and the small and large intestinal lamina propria were assessed. Data are the compilation of two independent experiments using
WT (n= 4-5) and Itk-/- mice (n= 4-5). Bar graphs with error bars show the averages and the SEMs. Statistical signiﬁcance was analyzed using Student’s t
tests (n.s., not signiﬁcant; *p < 0.05; **p < 0.01; ***p < 0.001). Source data are provided as a Source Data ﬁle
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ILC2, before and after IL-2c treatment. After IL-2c treatment, we
observed increased Annexin V on Itk−/− ILC2, while all other
populations were similar (Fig. 7e, f). These data indicate that the
increased numbers of ILC2 in IL-2c-treated Itk−/− mice are
undergoing a higher rate of apoptosis compared with all other
ILC2 populations. As IL-2 stimulation of T cells is known to
upregulate Bcl-241,42, we assessed Bcl-2 levels in intestinal ILC2,
before and after IL-2c injection. We ﬁrst observed that Itk−/−
intestinal ILC2 in both the siLP and the cLP had markedly
reduced Bcl-2 levels under steady-state conditions (Fig. 7g, h). In
response to IL-2c, Bcl-2 levels in Itk−/− ILC2 increased
substantially, and achieved levels comparable with those seen
in the respective WT ILC2 populations. Collectively, these
data support the conclusion that the defect in intestinal ILC2 in
Itk−/− mice results from impaired ILC2 survival in the intestinal
environment.
Discussion
In this study, we show that ITK deﬁciency speciﬁcally affects
ILC2 homeostasis in the intestine, but not of ILC2 residing in
other tissues, or of other innate ILC subsets, such as ILC1 and
ILC3. As reported previously, TCR signaling components and
cytokine receptors are known to be upregulated in ILC pre-
cursors during their early development upon the expression of
T-cell lineage transcription factors, e.g., TCF-1, GATA-3, and
Bcl11b22,23,26–28. However, the role of these genes in mature
ILC positioned in the peripheral tissues has not been well
characterized. Given CD25 expression among ILCs and the
responsiveness to IL-23,5,20,40, the function of ITK in ILC2
might be involved in IL-2-associated ILC2 homeostasis in the
periphery. In CD4+ T cells, ITK is required for TH2-mediated
responses, which are dependent on IL-2/STAT5-mediated sig-
naling43,44. Supporting this notion, STAT5 deﬁciency affects
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transferred to Rag1−/− Il2rg−/− hosts, and the proportions of ILC2 in the mLN and small or large intestinal LP were examined at D3 post transfer
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signiﬁcance was analyzed using Student’s t tests (n.s., not signiﬁcant; *p < 0.05; ***p < 0.001). Source data are provided as a Source Data ﬁle
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GATA-3 expression in intestinal ILC2 while RORγt expression
in ILC3 is largely normal45.
In response to viral infections, such as RSV, IAV, or rhino-
virus, lung-resident ILC2 are activated by tissue damage via the
production or release of IL-25 or IL-336,18,33,46–48. However, no
studies have examined potential changes in intestinal ILC2
following virus infection. Considering the increase in IL-25-
producing tuft cells after murine norovirus infection49, intest-
inal ILC2 numbers would be likely to increase, as is seen fol-
lowing intestinal parasite infections50,51. The role of intestinal
ILC2 during pathogen infection is to promote intestinal epi-
thelium integrity via IL-5, IL-13, and amphiregulin, which leads
goblet hyperplasia and mucus production11–13,18. Consistent
with these ﬁndings Itk−/− mice, having few ILC2 in the intes-
tine, displayed more severe responses to DSS-induced intestinal
tissue damage compared with WT mice; further, intestinal tis-
sue permeability of Itk−/− mice was greatly increased under
steady-state conditions. Although the severe response to DSS-
induced damage could be affected by a potential defect in
T cells in Itk−/− mice, DSS colitis is considered to be largely
dependent on innate immunity52. The onset of weight loss in
Itk−/− mice to DSS treatment is immediate (D1 of post treat-
ment), which argues against a contribution of T cells to disease
progression in DSS-treated Itk−/− mice.
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In the present study, we showed IL-2c injection restores
intestinal ILC2 numbers in Itk−/− mice, while IL-33 injection
failed to exert such an effect. As we observed comparable pro-
liferation of both WT and Itk−/− ILC2 to IL-33 in other organs
in vivo, it is possible that the initial number of gut ILC2 in Itk−/−
mice was too low to show robust expansion in the intestinal LP.
However, Itk−/− ILC2 in the intestine did exhibit extensive
expansion following IL-2c injection, with a fold expansion even
higher than seen for WT intestinal ILC2. Previous reports showed
that IL-2, a cytokine predominantly produced by CD4+ T cells,
promotes the proliferation, expansion, and also effector function
of ILC2, suggesting a reciprocal interaction between CD4+ T cells
and ILC216,19,40,53. This notion also correlates with our ﬁndings
of reduced CD4+ T-cell numbers in the intestinal mucosa, but
not the lungs, of Itk−/− mice under steady-state conditions
(Supplementary Fig. 8). Furthermore, as we observed comparable
gut-homing receptor expression on both WT and Itk−/− ILC2,
the intestinal ILC2 defect in Itk−/− mice is unlikely to be
accounted for by a cell-intrinsic migration defect, despite the
reduction in Itk−/− ILC2P seen 3 days after transfer of ILC2
precursors into Rag1−/− Il2rg−/− hosts.
Administration of IL-2/anti-IL-2 antibody complexes (JES6-
1A12) restored the population of intestinal ILC2 in Itk−/− mice.
Based on this ﬁnding, it is plausible that CD4+ T cells are
important in the tissue maintenance of ILC2 in the intestine via
IL-2 production. In these studies, we did not detect alterations in
the populations of conventional CD4+ or CD8+ T cells in the
intestinal tissue due to the preferential binding of the JES6-1A12/
IL-2 complexes to Treg over conventional T cells54–56. Future
studies are warranted to test whether adoptive transfer of CD4+
T cells or injection of IL-2 complexes formed with the S4B6 clone
of anti-IL-2 antibody into Itk−/− mice would lead to the recovery
of ILC2 in the gut tissues of these mice.
Gomez-Rodriguez et al. recently reported late defects of the
lung ILC2 in Itk−/− mice upon papain challenge, and their results
suggest that impaired T-cell function and IL-2 production may
result in these defects57. Despite a comparable lung ILC2 popu-
lation in WT and Itk−/− mice after intranasal MHV68 challenge
in our studies, our data on intestinal ILC2 support the notion that
reduced T-cell numbers are critical for ILC2 homeostasis in the
tissue. Gomez-Rodriguez et al. also reported that IL-2 or con-
stitutively active STAT5 restored the impaired effector function of
Itk−/− TH9 cells, a subset of effector CD4+ T cells with functional
similarity to ILC257. These data strengthen our conclusion that a
cell-intrinsic defect in Itk−/− ILC2 is due to impaired homeostasis
and survival, possibly related to insufﬁcient IL-2.
Our data indicate that IL-2 promotes the survival and persis-
tence of intestinal ILC2. One likely mechanism is IL-2-induced
activation of STAT5 leading to transcription of the STAT5 target
gene Bcl-245,58. Although IL-15 can also affect cell survival of ILC
via STAT5, IL-15-mediated signaling is not required for the
homeostasis of ILC245. Of note, CD122 expression levels in ILC2
are lower than those in ILC1 and ILC3, indicating that
STAT5 signaling in ILC2 would likely be more dependent on IL-
259. Interestingly, Villarino et al. suggested that this loss of
intestinal ILC2 in Stat5-deﬁcient mice is due to defects in later
development, i.e., tissue homing or peripheral homeostasis, not
due to defects in ILC2 progenitors45. These data align with our
conclusions, and support the notion that ITK is required in
ILC2 for optimal responses to IL-2/STAT5 signaling.
Consistent with this, Itk−/− ILC2 displayed reduced Bcl-2
expression even in response to in vivo IL-2 stimulation, similar
to that observed in Stat5-deﬁcient ILC245. Interestingly, we did
not detect increased proportions of apoptotic ILC2 in Itk−/−
intestines compared with WT under steady-state conditions. We
speculate that these apoptotic cells are rapidly cleared from the
tissue by resident macrophages or other phagocytic cells. Taken
all together, our data argue that the ITK-associated defect in
intestinal ILC2 is due to IL-2 availability in the microenviron-
ment along with impaired cell survival due to poor expression of
Bcl-2.
Overall, we show that ITK regulates ILC2 tissue homeostasis in
the intestine, and consequently, is required to promote intestinal
epithelium barrier integrity. These ﬁndings suggest that a deﬁciency
in ITK may affect the severity of enteric pathogen infection or
inﬂammatory bowel disease via impaired ILC2-mediated tissue
homeostasis.
Methods
Mice. C57BL/6 WT and congenic CD45.1 mice were purchased from Taconic
Biosciences. All purchased mice were maintained with Itk−/− in our vivarium for
several generations. C57BL/6 Rag1−/− Il2rg−/− mice were provided by Michael A.
Brehm (UMMS). C57BL/6 Il7ra-Cre x Roraﬂ/ﬂ were bred and maintained in the
animal facility of the Skirball Institute at NYU. Mice were housed in SPF condi-
tions in accordance with UMMS or NYU IACUC guidelines.
Antibodies for ﬂow cytometric analysis. Cells were stained with anti-mouse CD3
(145-2C11), CD11b (M1/70), CD11c (N418), CD19 (6D5), CD25 (PC61.5),
CD45.1 (A20), CD45.2 (104), CD90.2 (53-2.1), CD127 (A7R34), CD199 (eBioCW-
1.2), CD335 (29A1.4), IL-25R (MUNC33), integrin α4 (9F10), integrin β7
(FIB504), integrin α4β7 (DATK32), KLRG-1 (2F1), ST2 (RMST2-33), NK1.1
(PK136), Sca-1 (D7), TCRβ (H57-597), TCRγδ (eBioGL3), CXCR4 (L276F12),
GATA-3 (L50-823), RORγt (AFKJS-9), T-bet (4B10), IL-5 (TRFK5), IL-13
(eBio13A), amphiregulin (206220), and anti-rat IgG (BD Biosciences, BioLegend,
R&D, and Invitrogen).
MHV68 DNA copy number measurement via q-PCR. Tissue DNA samples were
subjected to q-PCR speciﬁc for viral gene ORF75c, and values were compared with
a standard curve generated using a plasmid containing ORF75c. PCR primers were
5′-AAATGGTGAAAGCCATTTTGA-3′ (forward) and 5′-CCACCATCGCA-
TAACAGTTG-3′ (reverse).
Lineage-depleted BM cell isolation and cell cultures. BM cells were counted and
Lin- BM cells were isolated with mouse Lineage Cell Depletion Kit (Miltenyi
Biotec). For cell proliferation assays, Lin− BM cells were labeled with CellTrace
Violet Cell Proliferation Kit (Invitrogen) and cultured in the presence of IL-2
(20 ng/mL, Invitrogen) ± IL-33 (50 ng/mL, R&D Systems) for 2 days. For gut-
homing receptor induction, Lin− BM cells were cultured with IL-2 (20 ng/mL), IL-
7 (20 ng/mL, Invitrogen), IL-33 (20 ng/mL) in the presence or absence of RA
(1.0 nM, Sigma-Aldrich) and/or TGF-β (5.0 ng/mL, R&D Systems) for 5 days. For
measuring CXCR4 expression in response to IL-33, Lin− BM cells were cultured
with IL-2 (10 ng/mL) ± IL-33 (1 to 10 ng/mL) plus or minus ITK inhibitor
PRN69460 (Principia Biopharma) for 3 days.
In vivo injection of IL-33 or IL-2 complexes. Mice received daily IP injections of
PBS or IL-33 (0.3 μg) seven times. For IL-2 complexes, mouse IL-2 (1.0 μg) and
anti-IL-2 (5.0 μg) (JES6-1A12, Invitrogen) were mixed and incubated at 37 °C for
30 min. Incubated IL-2 complex was given IP daily for 4 days.
Generation of BM chimeras. Harvested BM cells from WT (CD45.1 or GFP
reporter) and Itk−/− mice (CD45.2) were mixed in 1:1, 1:3, and 1:5 ratios. The WT
BM recipients were irradiated with 550 rad twice with a 4 h interval between doses.
A total of 2.0 × 107 BM cells were intravenously injected.
Adoptive transfer of BM ILC2P. Lin− BM cells were cultured with IL-2, IL-7, and
IL-33 plus RA and TGF-β for 3 days and then enriched with mouse CD25
MicroBead Kit. CD25-enriched Lin− BM cells (1.0 × 106 cells) were intravenously
injected to naïve Rag1−/− Il2rg−/− mice. Lymphocytes from mLN and intestinal
tissues were isolated at D3.
Dextran sodium sulfate-induced colitis. In total, 3.0% of DSS (MP Biomedicals)
was dissolved in the drinking water, and mice were treated for 5 days and then
changed to normal water for 10 days. Weight change was monitored daily, and in
some experiments, mice were killed at D7.
Measurement of intestinal permeability. Food and water were withdrawn for 6 h
and mice were orally administered FITC-dextran (Sigma-Aldrich) diluted in PBS
(60 mg/100 g). Serum was collected after 4 h and FITC-dextran level was measured
with a UV spectrophotometer.
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Statistical analysis. All statistical analyses were performed using Prism 7
GraphPad Software. Differences between individual groups were analyzed for
statistical signiﬁcance using Student’s t tests (*p < 0.05; **p < 0.01; ***p < 0.001).
Data availability
The authors declare that the data supporting this study are available within the paper and
its Supplementary Information. All other data are available from the authors upon
reasonable request. The source data underlying Figs. 1 to 7, and Supplementary Figures 1
to 7 are provided as a Source Data ﬁle.
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